Primecap Management Co. CA Sells 353,394 Shares of LivaNova PLC (NASDAQ:LIVN)

Primecap Management Co. CA lessened its holdings in LivaNova PLC (NASDAQ:LIVN) by 5.9% in the third quarter, Holdings Channel reports. The institutional investor owned 5,627,806 shares of the company’s stock after selling 353,394 shares during the period. Primecap Management Co. CA owned 0.10% of LivaNova worth $295,685,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Fifth Third Bancorp raised its holdings in LivaNova by 97.1% in the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after buying an additional 332 shares during the last quarter. Hexagon Capital Partners LLC increased its position in LivaNova by 117.8% during the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after purchasing an additional 370 shares during the period. Lazard Asset Management LLC acquired a new stake in LivaNova during the 1st quarter valued at approximately $84,000. Canada Pension Plan Investment Board acquired a new stake in LivaNova during the 2nd quarter valued at approximately $88,000. Finally, Acadian Asset Management LLC acquired a new stake in LivaNova during the 1st quarter valued at approximately $94,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Price Performance

Shares of NASDAQ:LIVN opened at $50.05 on Thursday. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The stock’s fifty day simple moving average is $51.96 and its two-hundred day simple moving average is $52.70. LivaNova PLC has a 1-year low of $42.75 and a 1-year high of $64.47. The stock has a market cap of $2.72 billion, a PE ratio of 119.17 and a beta of 1.01.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Robert W. Baird increased their target price on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Needham & Company LLC reissued a “buy” rating and set a $75.00 target price on shares of LivaNova in a research report on Tuesday, November 12th. The Goldman Sachs Group started coverage on shares of LivaNova in a research report on Friday, October 4th. They set a “buy” rating and a $65.00 target price for the company. Stifel Nicolaus raised their price objective on shares of LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Finally, StockNews.com downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 16th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $69.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.